Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S E Frey

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Vaccine|February 1, 1995
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, J H Rogers, J E Perry, et al.
Vaccine|June 12, 2003
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsP B Gilbert, Y-L Chiu, M Allen, et al.
The Journal of Infectious Diseases|October 9, 1999
Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccineS E Frey, C Harrison, R F Pass, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
Vaccine|March 10, 1998
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M J McElrath, T J Matthews, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Vaccine|February 1, 1995
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, J H Rogers, J E Perry, et al.
Vaccine|June 12, 2003
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsP B Gilbert, Y-L Chiu, M Allen, et al.
The Journal of Infectious Diseases|October 9, 1999
Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccineS E Frey, C Harrison, R F Pass, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
Vaccine|March 10, 1998
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M J McElrath, T J Matthews, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
Pageof 2